Avient (AVNT)

NYSEMaterialsChemicals - SpecialtySnapshot 2026-10-23

$41.03+1.11%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Avient’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+0.5%

+10% or more+5%0%−5%−10% or less

3.53 → 3.55 EPS · FY ending Dec 31, 2027 · 5 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 5 to 5; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q3
EBITDA	$575M–$603Mnon-GAAP	—
FY 2026 · Q4
Revenue	—	803M
EPS	—	0.606
FY 2026 · Annual
Revenue	—	3.42B
EPS	$3.1–$3.25non-GAAP	3.2
Eps growth	10%–15%non-GAAP	—
FY 2027 · Annual
Revenue	—	3.53B
EPS	—	3.549

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain full year adjusted EPS near $3.05	The company aims for full year EPS near $3.05.	Intact	Adjusted EPS falls below $2.93 or above $3.17 in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Free cash flow above $200 million	Free cash flow is expected above $200 million in 2026.	Intact	Free cash flow falls below $200 million in FY26	Free cash flow: $-64.8M FY2026-Q2; GAAP. Published target: >= $200 million free cash flow. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-64,800,000 USD · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Adjusted EBITDA margin near 17.7%	A primary condition in Avient's published investment case. The stated target is >= 17.7% adjusted EBITDA margin.	Intact	Adjusted EBITDA margin falls below 17.5%	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA margin expanded from 16.7% in 2025-Q4 to 18.3% in 2026-Q2, reflecting management's focus on productivity and cost control. The margin expansion trajectory matches management's stated priority and supports earnings growth. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$3.55

$3.38 → $3.55 · observed estimates

FY2027 revenue$3.53B

$3.50B → $3.53B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$3.38	$3,499,297,740	8 / 8
2026-07-25	$3.38	$3,499,297,740	8 / 8
2026-07-26	$3.38	$3,499,297,740	8 / 8
2026-07-27	$3.38	$3,499,297,740	8 / 8
2026-07-28	$3.38	$3,499,297,740	8 / 8
2026-07-29	$3.38	$3,499,297,740	8 / 8
2026-07-30	$3.38	$3,499,297,740	8 / 8
2026-07-31	$3.38	$3,499,297,740	8 / 8
2026-08-01	$3.38	$3,499,297,740	8 / 8
2026-08-02	$3.38	$3,499,297,740	8 / 8
2026-08-03	$3.38	$3,499,297,740	8 / 8
2026-08-04	$3.38	$3,497,111,092	5 / 6
2026-08-05	$3.38	$3,499,297,740	8 / 8
2026-08-06	$3.38	$3,499,297,740	8 / 8
2026-08-07	$3.38	$3,497,111,092	5 / 6
2026-08-08	$3.47	$3,526,565,100	8 / 8
2026-08-09	$3.47	$3,526,565,100	8 / 8
2026-08-10	$3.47	$3,526,565,100	8 / 8
2026-08-11	$3.50	$3,523,794,770	8 / 8
2026-08-12	$3.50	$3,523,794,770	8 / 8
2026-08-13	$3.50	$3,523,794,770	8 / 8
2026-08-14	$3.38	$3,497,111,092	5 / 6
2026-08-15	$3.38	$3,497,111,092	5 / 6
2026-08-16	$3.38	$3,497,111,092	5 / 6
2026-08-17	$3.38	$3,497,111,092	5 / 6
2026-08-18	$3.38	$3,497,111,092	5 / 6
2026-08-19	$3.38	$3,497,111,092	5 / 6
2026-08-20	$3.38	$3,497,111,092	5 / 6
2026-08-21	$3.53	$3,532,856,315	5 / 6
2026-08-22	$3.53	$3,532,856,315	5 / 6
2026-08-23	$3.53	$3,532,856,315	5 / 6
2026-08-24	$3.53	$3,532,856,315	5 / 6
2026-08-25	$3.53	$3,532,856,315	5 / 6
2026-08-26	$3.53	$3,532,856,315	5 / 6
2026-08-27	$3.53	$3,532,856,315	5 / 6
2026-08-28	$3.53	$3,532,856,315	5 / 6
2026-08-29	$3.53	$3,532,856,315	5 / 6
2026-08-30	$3.53	$3,532,856,315	5 / 6
2026-08-31	$3.53	$3,532,856,315	5 / 6
2026-09-01	$3.53	$3,532,856,315	5 / 6
2026-09-02	$3.53	$3,532,856,315	5 / 6
2026-09-03	$3.53	$3,532,856,315	5 / 6
2026-09-04	$3.53	$3,532,856,315	5 / 6
2026-09-05	$3.53	$3,532,856,315	5 / 6
2026-09-06	$3.53	$3,532,856,315	5 / 6
2026-09-07	$3.53	$3,532,856,315	5 / 6
2026-09-08	$3.53	$3,532,856,315	5 / 6
2026-09-09	$3.53	$3,532,856,315	5 / 6
2026-09-10	$3.53	$3,532,856,315	5 / 6
2026-09-11	$3.53	$3,532,856,315	5 / 6
2026-09-12	$3.53	$3,532,856,315	5 / 6
2026-09-13	$3.53	$3,532,856,315	5 / 6
2026-09-14	$3.53	$3,532,856,315	5 / 6
2026-09-15	$3.53	$3,532,856,315	5 / 6
2026-09-16	$3.53	$3,532,856,315	5 / 6
2026-09-17	$3.53	$3,532,856,315	5 / 6
2026-09-18	$3.53	$3,532,856,315	5 / 6
2026-09-19	$3.53	$3,532,856,315	5 / 6
2026-09-20	$3.53	$3,532,856,315	5 / 6
2026-09-21	$3.53	$3,532,856,315	5 / 6
2026-09-22	$3.53	$3,532,856,315	5 / 6
2026-09-23	$3.53	$3,532,856,315	5 / 6
2026-09-24	$3.53	$3,532,856,315	5 / 6
2026-09-25	$3.53	$3,532,856,315	5 / 6
2026-09-26	$3.53	$3,532,856,315	5 / 6
2026-09-27	$3.53	$3,532,856,315	5 / 6
2026-09-28	$3.53	$3,532,856,315	5 / 6
2026-09-29	$3.53	$3,532,856,315	5 / 6
2026-09-30	$3.53	$3,532,856,315	5 / 6
2026-10-01	$3.53	$3,532,856,315	5 / 6
2026-10-02	$3.53	$3,532,856,315	5 / 6
2026-10-03	$3.53	$3,532,856,315	5 / 6
2026-10-04	$3.53	$3,532,856,315	5 / 6
2026-10-05	$3.53	$3,532,856,315	5 / 6
2026-10-06	$3.53	$3,532,856,315	5 / 6
2026-10-07	$3.53	$3,532,856,315	5 / 6
2026-10-08	$3.53	$3,532,856,315	5 / 6
2026-10-09	$3.53	$3,532,856,315	5 / 6
2026-10-10	$3.53	$3,532,856,315	5 / 6
2026-10-11	$3.53	$3,532,878,538	5 / 6
2026-10-12	$3.53	$3,532,878,538	5 / 6
2026-10-13	$3.53	$3,532,878,538	5 / 6
2026-10-14	$3.55	$3,532,878,538	5 / 6
2026-10-15	$3.55	$3,532,878,538	5 / 6
2026-10-16	$3.55	$3,532,878,538	5 / 6
2026-10-17	$3.55	$3,532,878,538	5 / 6
2026-10-18	$3.55	$3,533,626,638	5 / 6
2026-10-19	$3.55	$3,533,626,638	5 / 6
2026-10-20	$3.55	$3,533,626,638	5 / 6
2026-10-21	$3.55	$3,533,637,749	5 / 6
2026-10-22	$3.55	$3,533,637,749	5 / 6
2026-10-23	$3.55	$3,533,637,749	5 / 6
2026-10-24	$3.55	$3,533,637,749	5 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	5	2
2026-06-01	6	2
2026-07-01	5	2
2026-08-01	5	2
2026-09-01	5	2
2026-10-01	5	3

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BarclaysOct 12

$44.00New observation · no comparable prior

$0$24.20$48.40

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain full year adjusted EPS near $3.05Direct metric needs a verified mapping
Free cash flow above $200 millionFree cash flow: $-64.8M
Adjusted EBITDA margin near 17.7%Direct metric needs a verified mapping

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.2%Typical daily move · historical

Downside history

-25.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Avient outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

AVNT is an execution-led industrial growth story, with recent results supporting the thesis rather than a clear turnaround. The thesis is intact, but earnings quality is fragile, so continued delivery matters.

What's priced into Avient

Valuation is described as cheap versus peers, and the evidence labels expectations as justified rather than unusually fragile. The expectations gap is negative, but the snapshot does not explain its scale in plain terms, so it is not a basis for a stronger valuation claim.

What the fundamentals likely do

Near term, recent earnings beats and higher 2026 adjusted EPS guidance support the current growth trajectory. Margin expansion and debt repayment show progress on cost control and the balance sheet. Risk remains moderate, with a history of a deep miss and recent peer misses; the sector backdrop is a headwind.

What Avient hinges on

Over the next several quarters, the thesis depends on management sustaining the raised guidance without a reversal that could damage credibility. Continued margin gains and debt reduction would support execution. Results and guidance from sector peers LIN, SHW, and ECL could either reinforce or weaken the sector backdrop.